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To determine the effectiveness of uzarigenin on S. aureus, the agar 
disk diffusion method was first completed to study the cytotoxicity effect of 
uzarigenin directly on the bacteria. A cytotoxicity assay was then 
completed to test the cytotoxicity of the uzarigenin on the human epithelial 
fibroblasts themselves. After, a TCID50 assay was used to test for a 
preventative dose of uzarigenin against S. aureus to determine at what 
dilutions the uzarigenin can protect the cells from infection at least 50% of 
the time. 
It was found that there was an average 8.5 mm zone of inhibition 
compared to a standard 26.4 mm zone of inhibition by tetracycline. Since 
there may be different diffusion rates, S. aureus may be resistant to 
uzarigenin.  It was also found that the uzarigenin caused cytopathic 
effects (CPE, changes in the host cell morphology due to infection) on the 
human epithelial fibroblasts up until a dilution of 10-6. Additionally, the 10-6
and 10-9 dilutions of uzarigenin were effective in combatting an infection 
from S. aureus, leaving little to no traces of cytopathic effects. However, 
dilutions further than 10-9 seemed to be too diluted to combat an infection, 
which resulted in CPE in all or most of the wells. Furthermore, the 
preventative dose for uzarigenin against S. aureus was found to be 1011.2. 














6 96-well plates • Human Epithelial Fibroblasts • Culture flasks • Cell scraper • E-MEM 10% FBS • HBSS • Sterile 
Dilution Tubes • Sterile Pipettes • Decontamination Pan • Tripticase Soy Agar Plate • Sterile Swab • S. aureus
culture • Tetracycline Disk • 1 mg Uzarigenin • 6mm paper disks 
Methods:
Agar Diffusion Method
First, 3 6 mm paper disks were soaked in 0.5 mL of 1 mg/mL uzarigenin for 24 hours. After 24 hours, a Tripticase 
soy agar plate was covered with S. aureus using a sterile cotton swab and a line was drawn on the outside of the 
plate to separate two halves. On one half, one uzarigenin disk was placed on the bacterial lawn and on the other 
half, a tetracycline disk, used as a standard, was placed on the bacterial lawn. The plate was incubated right side 
up at 30℃ for 24 hours and then examined. This was repeated 3 times.
Cytotoxicity Test
The cells were first examined under a microscope to see if they were confluent. The medium was then poured off 
from the flask and 5 mL of HBSS was added. Next, 4.5-5 mL of 1.05 cells/mL suspension was made in E-MEM 
10% FBS and the cells were scraped. After, 2 mL of E-MEM was added to the flask. In the meantime, 10-fold 
dilutions of 0.5 mL of 1 mg/mL uzarigenin 10-3 to 10-16 were made in E-MEM 10% FBS. Next, 0.1 mL of E-MEM 10
% FBS was added to each well H 1-5 in a 96-well plate. Then, 0.1 mL of uzarigenin dilutions were added in 
replicates of 5 by starting with the most dilute dilution in row G to the least dilute dilution in row A. Then, 0.1 mL of 
the cell suspension were added to each well. The plates were incubated at 37℃ in the CO2 incubator and 
monitored for 3 days. This was repeated 3 times.
Preventative Dose
The protocol for the preventative dose is the same as the cytotoxicity test except only the uzarigenin dilutions 10-6  
to 10-12 were used. Also, 0.1 mL of S. aureus diluted to 10-6 was added to each well except the wells in row H. This 
was repeated 3 times.
Based on the standards from tetracycline in the agar disk diffusion 
method, the S. aureus may be resistant to uzarigenin. This is because the 
zone of inhibition is less than 10mm. However, this may be due to uzarigenin 
not diffusing in the agar as well as tetracycline. It is unclear if the S. aureus is 
susceptible to the uzarigenin.
In the cytotoxicity assay, it was found that uzarigenin was toxic to the 
human epithelial fibroblasts up until a dilution of 10-6. This was characterized 
by the presence of CPE in all of the wells for dilution 10-3 to 10-5.
When finding the preventative dose, it was found that uzarigenin was 
effective in combatting a bacterial infection of S. aureus at dilutions 10-6
through 10-9, but was most effective at dilutions 10-8 and 10-9 where no CPE 
was detected in all three trials. It is presumed that after uzarigenin is diluted 
further than 10-9, it is too diluted to combat the S. aureus.
Furthermore, a TCID50 calculation was completed to show the 
preventative dose of uzarigenin. This was calculated to be 1011.2 which 
means up until a dilution of 10-11.2 uzarigenin will be able to protect the cells 
from bacterial infection at least 50% of the time.
Overall, there was an effect of uzarigenin on the S. aureus, though in 
the agar disk diffusion method, it was not as pronounced as the tetracycline 
effect. In conclusion, uzarigenin may be able to act as an antiseptic against 
S. aureus.
Discussion
Impetigo, bullous impetigo, and Staphylococcal scalded skin 
syndrome are common, superficial, bacterial skin infections that are 
caused by Staphylococcus aureus. Impetigo is characterized by an 
inflamed and infected epidermis. There is also a rare variant which on the 
mild end of the spectrum is bullous impetigo, and on the more severe end 
is Staphylococcal scalded skin syndrome. Both skin infections are 
represented by widespread painful blistering of the skin. Currently, the 
topical treatments for these infections include use of fusidic acid and 
mupirocin (Johnston, 2014). Though mupirocin and fusidic acid were 
noted as effective treatments, researchers discovered in 1987 that S. 
aureus can form resistance to these medications (Delaney, 2013) 
(Doudoulakakis, 2017). Since there is noted resistance by S. aureus to 
existing medications, new treatments are being studied. 
In order to find other possible treatments, the chemical structures of 
mupirocin and fusidic acid were first studied and compared to other 
chemicals. After extensive research, the existing treatments for these 
infections were found to have a similar chemical structure to uzarigenin. In 
further research, uzarigenin was found to be in a plant called Pergularia 
daemia (Ramanathan, 2013). The uzarigenin in this plant has shown to 
have microbial effects in previous studies, especially against S. aureus. 
This leads to a motive to further study uzarigenin and question, “Can 
uzarigenin be used as an antiseptic?” The purpose of this lab is to test if 
uzarigenin can be used as an antiseptic and at what dilutions is it most 
effective. It is hypothesized that if uzarigenin is an antiseptic, it will kill 
most or all of the infection on human epithelial fibroblasts. It will also 















Calculation 2: Finding the ID50
(𝑙𝑜𝑔	𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑎𝑏𝑜𝑣𝑒	50%) + (𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑎𝑡𝑒	𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒	𝑥	𝑙𝑜𝑔	𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑓𝑎𝑐𝑡𝑜𝑟) = 	 𝐼𝐷FG
(-10) + (0.167 x -1.0) = -10.167
ID50 = 1010.2
Calculation 3: Finding the TCID50/ml
ID50/ Volume Used = TCID50/ml
1010.2 TCID50 / 0.1 ml = 10 x 1010.2 TCID50/ml = 1011.2  TCID50/ml
Figure	4:	Percentage	of	Wells	with	CPE	
for	Trial	1,	Day	3
Figure	5:	Percentage	of	Wells	with	CPE	
for	Trial	2,	Day	3
Figure	6:	Percentage	of	Wells	with	CPE	
for	Trial	3,	Day	3
Figure	7:	Trial	
3,	Control	
Well	3
Figure	8:	Trial	
3,	10-9 Dilution	
Well	3		
Figure	9:	Trial	
3,	10-11
Dilution	Well	3
Figure	3:	Preventative	Dose	Trials	1-3
